EMT is also associated with tumor budding, which accounts for gemcitabine resistance; a study indicated that tumor budding with vimentin expression becomes a key process in pancreatic cancer and is responsible for progression and gemcitabine resistance [69]. The gene discussed is VIM; the disease is familial pancreatic carcinoma.